医用透析器智能装配成套设备

Search documents
创新领航破局突围多维铸就智造标杆 迈得医疗2024年实现营收2.75亿元
Quan Jing Wang· 2025-05-01 01:18
Company Performance - Maider Medical achieved an annual revenue of 275 million yuan with a comprehensive gross margin of 43.56% [1] - Revenue from blood purification and safe infusion line machines reached 104 million yuan and 116 million yuan, with gross margins of 51.81% and 39.44% respectively [1][3] - The company reported a 39.38% year-on-year increase in overseas revenue, totaling 17.63 million yuan, with a gross margin of 44.90%, surpassing domestic sales by 1.43 percentage points [3] R&D and Innovation - The company invested 40.41 million yuan in R&D, a 21.81% increase year-on-year, accounting for 14.70% of total revenue [1][5] - Maider Medical submitted 146 patent applications during the reporting period, including 21 invention patents, and received 78 new patent authorizations [5] - The company has a total of 416 authorized patents, including 195 invention patents, and has actively participated in drafting national and provincial standards [5][7] Market Position and Strategy - Maider Medical is recognized as a leading supplier of dialysis consumables and has maintained the highest market share in the industry for three consecutive years from 2021 to 2023 [3] - The company is focusing on expanding its product matrix in the contact lens business and has successfully obtained multiple medical device registration certificates [4] - The company aims to enhance its operational efficiency and expand its medical equipment industry chain by advancing its smart medical consumables project and technology center [4][6] Industry Trends - The global medical device market reached a size of 582.6 billion USD in 2023, growing by 5.40% year-on-year, while China's market exceeded 1 trillion yuan, reaching 1,032.8 billion yuan [2] - The medical device industry is transitioning towards high-quality development, driven by policy support, market expansion, and automation in production [2] - The company is positioned to leverage the opportunities presented by the aging population and the advancement of manufacturing strategies in China [1][2]